This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo continues to experience long-term OS benefit as demonstrated by the long-term pooled efficacy and safety results in patients with previously-treated NSCLC.
Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally
by Zacks Equity Research
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
4 Big Drugmakers Boasting Impressive Oncology Pipelines
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
ACADIA Surges on Early Success of Nuplazid Dementia Study
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) Parkinson's psychosis drug, Nuplazid, meets primary endpoint earlier than expected in late-stage label expansion study evaluating it in patients with dementia-related psychosis.
Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA
by Zacks Equity Research
The FDA grants a Breakthrough Therapy status to Novartis' (NVS) capmatinib for the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs
by Kinjel Shah
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer
by Zacks Premium Research
The latest EU nod makes Roche's (RHHBY) immuno-oncology drug -- Tecentriq -- the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC in Europe.
AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC
by Zacks Equity Research
AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M
by Zacks Equity Research
Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.
AstraZeneca's Lupus Drug Meets Primary Endpoint in Study
by Zacks Equity Research
AstraZeneca's (AZN) second phase III study evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus meets the primary endpoint.
Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs
by Kinjel Shah
Oklahoma imposes fine of $572 million on J&J (JNJ). FDA gives nod to Lilly's (LLY) Taltz while EU approves Bristol-Myers' (BMY) Empliciti and Roche's (RHHBY) Tecentriq for expanded patient population.
Forget Pfizer, Add These Big Drugmakers to Your Portfolio
by Kinjel Shah
Buy these three large drug companies instead of Pfizer (PFE) as the stock is down this year.
AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease
by Zacks Equity Research
AstraZeneca's (AZN) Fasenra gets Orphan Drug status for eosinophilic oesophagitis (EoE). A phase III COPD study on Breztri Aerosphere meets primary endpoint.
Here's Why Merck (MRK) is Outperforming Its Industry Of Late
by Zacks Equity Research
Merck's shares are up 11.9% this year so far on strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
AstraZeneca's Farxiga Gets Fast Track Tag for Renal Outcome
by Zacks Equity Research
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to delay progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease.
Inovio (INO) Down More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
Inovio (INO) stops the development of INO-5401 for advanced bladder cancer, and cuts workforce by 28% and annual burn rate by 25% as part of the restructuring process.
Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit
by Kinjel Shah
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.
Roche's Tecentriq Gets Japan's Nod for Small Cell Lung Cancer
by Zacks Equity Research
Roche (RHHBY) gets approval for Tecentriq in Japan for extensive-stage SCLC.
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
by Zacks Equity Research
AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.
Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
by Kinjel Shah
FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.
AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL
by Zacks Equity Research
The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.
Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
by Zacks Equity Research
Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.
Agios Rides High on Tibsovo Sales Amid Acute Competition
by Zacks Equity Research
Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.
Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.